目的:评估SARS-CoV-2感染的流行和特征,和患病率,功效,垂体疾病患者抗SARS-CoV-2疫苗接种的安全性。
方法:观察性,在参考中心随访的成人垂体疾病患者的横断面研究。收集临床资料和一份关于SARS-CoV-2感染的问卷,应用了疫苗接种及其可能的不良反应。COVID-19疾病严重程度定义为轻度,中度,根据世界卫生组织的分类,严重。
结果:研究了145例患者(79名妇女;年龄50±15.8岁;垂体疾病持续时间16.8±11.5年),脑垂体疾病的病因为肿瘤的74.5%,45.9%的患者因ACTH缺乏而接受糖皮质激素替代治疗。确诊SARS-CoV-2感染51例(35.2%;32名女性;年龄53.8±14.8岁,22接种前),28人(54.9%),17例(33.3%)和6例(11.8%)轻度,中度,和严重的疾病,分别,7例(14%)患者需要住院治疗。1例轻度病例在SARS-CoV-2感染后出现垂体卒中。高龄是COVID-19的危险因素。中度和重度COVID-19患者的血脂异常和垂体疾病持续时间较高。除一名参与者外,所有参与者都接种了COVID-19疫苗,60.4%的参与者出现了不良事件,最常见的局部疼痛(54.0%),发烧(33.3%),头痛(18.4%),1例脱发和2例持续性疲劳。
结论:我们队列中SARS-CoV-2感染率为35.2%,包括14%需要住院治疗的中度和重度病例。疫苗接种是普遍和安全的。
OBJECTIVE: To evaluate the prevalence and characteristics of SARS-CoV-2 infection, and the prevalence, efficacy, and safety of anti-SARS-CoV-2 vaccination in patients with pituitary diseases.
METHODS: Observational, cross-sectional study of adult patients with pituitary diseases followed in a reference center. Clinical data were collected and a questionnaire about SARS-CoV-2 infection, vaccination and its possible adverse effects was applied. COVID-19 disease severity was defined as mild, moderate, and severe according to the WHO classification.
RESULTS: 145 patients were studied (79 women; age 50 ± 15.8 years; duration of pituitary disease 16.8 ± 11.5 years), the cause of pituitary disease was tumoral in 74.5%, and 45.9% were on glucocorticoid replacement due to ACTH deficiency. SARS-CoV-2 infection was confirmed in 51 patients (35.2%; 32 women; age 53.8 ± 14.8 years, 22 before vaccination), with 28 (54.9%), 17 (33.3%) and 6 (11.8%) cases of mild, moderate, and severe disease, respectively, and hospitalization was indicated in 7 (14%) cases. One mild case presented pituitary apoplexy after SARS-CoV-2 infection. Advanced age was a risk factor for COVID-19. Patients with moderate and severe forms of COVID-19 had higher prevalence of dyslipidemia and duration of pituitary disease. All but one of the participants were vaccinated against COVID-19, and 60.4% had adverse events, the most common local pain (54.0%), fever (33.3%), and headache (18.4%), with one case of alopecia and two of persistent fatigue.
CONCLUSIONS: The prevalence of SARS-CoV-2 infection in our cohort was 35.2%, including 14% of moderate and severe cases requiring hospitalization. The vaccination was universal and safe.